

Supplementary Table 7. Overview of Incidence of Patients With a Positive ADA Assay Response (Immunogenicity Population)

	Sarilumab 200 mg q2w (n=184)
Peak titer	
Min:max	30.0:120.0
Patients with a persistent* positive response, n (%)	5/184 (2.7)
Neutralizing†	0/184
Non-neutralizing	5/184 (2.7)
Persistent based on last sample	5/184 (2.7)
Patients with a transient‡ positive response, n (%)	8/184 (4.3)
Neutralizing†	0/184
Non-neutralizing	8/184 (4.3)

*Persistent positive response: treatment-emergent positive ADA detected at 2 or more consecutive sampling time points during the AE period, where the first and last ADA-positive samples were separated by a period of at least 16 weeks. Also persistent in case last sample analyzed was positive.

†At least one postbaseline measurement classified as neutralizing positive.

‡Transient positive response is defined as any positive ADA assay response that is not considered persistent. ADA, antidrug antibody; AE, adverse event; q2w, every 2 weeks.